Biography and Research Information

OverviewAI-generated summary

Cesar Gentille's research focuses on the clinical outcomes of patients undergoing advanced immunotherapies for hematologic malignancies. His work investigates the efficacy and adverse events associated with treatments such as CAR-T cell therapy and bispecific T-cell engagers, particularly in relapsed or refractory settings like diffuse large B-cell lymphoma (DLBCL). Gentille has examined specific complications, including cardiotoxicity triggered by cytokine release syndrome following CAR-T therapy, and has explored the impact of opportunistic infections in patients treated with daratumumab for multiple myeloma.

His publications also address the development of novel treatment combinations, such as mogamulizumab in combination with other agents for Sézary syndrome. Gentille collaborates with researchers at the University of Arkansas for Medical Sciences, including Toshali Pandey, Curran Henson, Grant M. Spears, and Bhavesh Mohan Lal. His current metrics include an h-index of 1 with a total of 7 publications and 12 citations.

Metrics

  • h-index: 1
  • Publications: 7
  • Citations: 12

Selected Publications

  • Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026) DOI
  • Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome (2025) DOI

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics